Gregory Kirkner
Overview
Explore the profile of Gregory Kirkner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sella T, Sorouri K, Rosenberg S, Loucks M, Kirkner G, Snow C, et al.
Cancer
. 2024 Sep;
131(1):e35585.
PMID: 39342485
Background: Following breast cancer (BC), many young women are interested in future childbearing and some may wish to breastfeed. However, limited information is available regarding their lactation experiences. Methods: Participants...
2.
Jovanovic B, Church S, Gorman K, North K, Richardson 3rd E, DiLullo M, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4768-4779.
PMID: 39136550
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying...
3.
Grinshpun A, Russo D, Ma W, Verma A, Hermida-Prado F, Sherman S, et al.
NPJ Breast Cancer
. 2024 Jun;
10(1):42.
PMID: 38851818
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone receptor-positive breast cancer. These mutations confer endocrine resistance that remains...
4.
Tarantino P, Gupta H, Hughes M, Files J, Strauss S, Kirkner G, et al.
Nat Commun
. 2023 Dec;
14(1):8321.
PMID: 38097580
No abstract available.
5.
Tarantino P, Gupta H, Hughes M, Files J, Strauss S, Kirkner G, et al.
Nat Commun
. 2023 Nov;
14(1):7496.
PMID: 37980405
The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast cancer undergoing next-generation sequencing from 7/2013-12/2020,...
6.
Sorouri K, Sella T, Rosenberg S, Loucks M, Kirkner G, Snow C, et al.
Cancer
. 2023 Oct;
130(4):517-529.
PMID: 37880931
Background: Breast cancer (BC) is the most common malignancy in women of reproductive age. This study sought to explore the postcancer conception and pregnancy experience of young BC survivors to...
7.
Guzman-Arocho Y, Rosenberg S, Garber J, Vardeh H, Poorvu P, Ruddy K, et al.
Br J Cancer
. 2021 Oct;
126(2):302-309.
PMID: 34703009
Background: Breast cancer in young women is more likely to have higher risk features and be associated with germline BRCA1/BRCA2 mutations. We present the clinicopathologic features of breast cancers in...
8.
Lin J, Morikawa T, Chan A, Kuchiba A, Shima K, Nosho K, et al.
Cancer Res
. 2012 Apr;
72(12):3020-8.
PMID: 22511578
Experimental studies have shown that estrogen- or progesterone-activated signaling leads to growth inhibition effects on colon cancer cells through the upregulation of several cell-cycle regulators. However, epidemiologic studies evaluating hormone...
9.
Abrams T, Brightly R, Mao J, Kirkner G, Meyerhardt J, Schrag D, et al.
J Clin Oncol
. 2011 Jul;
29(24):3255-62.
PMID: 21768462
Purpose: Previous studies have examined predictors for initiation of adjuvant chemotherapy in stages II and III colon cancer. However, little is known regarding the use of specific chemotherapy regimens or...
10.
Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, et al.
Mod Pathol
. 2005 Aug;
19(1):59-68.
PMID: 16118624
Signet ring cell carcinoma and mucinous carcinoma are distinct subtypes of colorectal adenocarcinoma. The morphologic and molecular spectra of colorectal carcinomas with various signet ring cell components and colorectal carcinomas...